Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
Cancers · 23.02.2025 · 17 (5) · 755
DOI: 10.3390/cancers17050755 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.02.2025. Verfasst von Kyli Berkley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Illinois Chicago, Chicago, IL 60607, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor that is strongly implicated in various cancers. In its canonical signaling pathway, Janus kinases (JAKs) phosphorylate STAT3 at the Y705 residue in response to cytokines or growth factors, with pY705 serving as a key marker of STAT3 oncogenic activity. Elevated pY705 levels correlate with poor prognosis, and numerous small-molecule inhibitors have been developed to block this phosphorylation site. More recently, phosphorylation at the S727 residue (pS727) has emerged as a critical contributor to STAT3-mediated oncogenesis, particularly due to its role in mitochondrial translocation. Evidence suggests that pS727 may even surpass pY705 in driving oncogenic activity. These findings prompt an important question: Which residue should be prioritized for effective STAT3 inhibition in cancer therapy?
Methods
This review compiles and critically analyzes the current literature on STAT3 inhibitors targeting pY705 and/or pS727, evaluating their therapeutic efficacy in vitro, in vivo, and in clinical trials. We assess the unique effects of targeting each residue on downstream signaling, toxicity, and clinical outcomes.
Results
Our analysis indicates that inhibitors targeting both pY705 and pS727 achieve the greatest therapeutic effectiveness. However, pS727 targeting is associated with higher toxicity risks.
Conclusions
Comprehensive evaluation of STAT3 inhibitors underscores the importance of targeting pY705 for maximum therapeutic benefit. The analysis also shows that co-targeting pS727 may increase overall efficacy. However, pS727 inhibition should be approached with lower affinity to minimize toxicity and enhance the clinical feasibility of dual-targeting strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, University of Illinois Chicago, Chicago, IL 60607, USA.
ORCID-Profile: Kyli Berkley, Julian Zalejski, Ashutosh Sharma
Zitieren
APA
Berkley, K., Zalejski, J., & Sharma, A. (2025). Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?. Cancers, 17(5), 755. https://doi.org/10.3390/cancers17050755
Vancouver
Berkley K, Zalejski J, Sharma A. Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?. Cancers. 2025;17(5):755. doi:10.3390/cancers17050755
BibTeX
@article{Berkley2025,
author = {Berkley, Kyli and Zalejski, Julian and Sharma, Ashutosh},
title = {Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?},
journal = {Cancers},
year = {2025},
volume = {17},
number = {5},
pages = {755},
doi = {10.3390/cancers17050755}
}
EUVIMED